Pre-Made Docaravimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Docaravimab benchmark antibody ( Whole mAb (Mouse), anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-150
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Docaravimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody |
---|---|
INN Name | Docaravimab |
Target | Rabies Virus Strain ERA GP Ectodomain Epitope G-III |
Format | Whole mAb (Mouse) |
Derivation | NA |
Species Reactivity | Human |
CH1 Isotype | IgG2b |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2019 |
Year Recommended | 2020 |
Companies | Candila Healthcare |
Conditions Approved | Rabies |
Conditions Active | NA |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | Rabies Virus Strain ERA GP Ectodomain Epitope G-III |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide